Drug developments for cancer immunotherapy focus on developing not only technology to directly attack tumor cells with effector cells or molecules (such as chimeric antigen receptor (CAR)-T or T cell receptor (TCR)-T) but also cargoes that activate the immune system by targeting different steps for producing an immune response (such as programmed cell death protein 1 (PD1) monoclonal antibodies, cytotoxic T lymphocyte-associated antigen-4 (CTLA4) monoclonal antibodies, cancer vaccines, and cytokines) [12,13,14]. Here, PDCD1 is linked to neoplasm.